文献速递白血病造血干细胞移植与细胞治疗

CAR-T细胞疗法作为老年B-ALL首次完全缓解的巩固治疗

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.
PubMed 文献 · Blood Adv · 2026-01-01

一项1期研究评估CD19 CAR-T细胞作为≥55岁B-ALL首次完全缓解(CR1)患者巩固治疗的安全性和疗效。18例患者接受淋巴细胞清除后输注记忆富集CD19 CAR-T细胞,中位年龄64岁,输注前均MRD阴性。无剂量限制毒性、≥2级细胞因子释放综合征或任何级别ICANS;估计18个月无事件生存率和总生存率分别为84%和100%。

要点

  • ≥55岁B-ALL CR1且MRD阴性患者中,CD19 CAR-T巩固治疗安全性良好。
  • 未观察到剂量限制毒性、≥2级CRS或任何级别ICANS。
  • 估计18个月EFS为84%,OS为100%,支持早期CAR-T治疗进一步研究。

核心结论

  • 一线CAR-T细胞治疗安全且耐受良好,可能延长MRD阴性CR1患者的缓解。

研究设计与样本

  • 1期研究,纳入18例≥55岁B-ALL首次完全缓解患者,中位年龄64岁,输注前均MRD阴性。
  • 患者接受淋巴细胞清除后输注记忆富集CD19 CAR-T细胞。
  • 试验注册号NCT05707273。

主要发现

  • 无剂量限制毒性、≥2级细胞因子释放综合征或任何级别免疫效应细胞相关神经毒性综合征。
  • 估计18个月无事件生存率为84%,总生存率为100%。
  • CAR-T细胞在血液和脑脊液中扩增,尽管患者MRD阴性。
  • 与历史试验(NCT02146924)复发/难治B-ALL患者相比,复发/难治患者血液和CAR-T细胞产品分别呈高炎症和高免疫代谢状态。

临床怎么用

  • 对于≥55岁B-ALL CR1且MRD阴性患者,可考虑CD19 CAR-T作为巩固治疗,但需进一步研究验证。

局限性

  • 1期研究样本量小(18例),需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a phase 1 study assessing the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cells as definitive consolidation in older adults (aged ≥55 years) with B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission (CR1). Eighteen patients received lymphodepletion followed by infusion of memory-enriched CD19 CAR T cells. The median age was 64 years, and all patients were measurable residual disease (MRD)-negative before lymphodepletion. There were no dose-limiting toxicities, grade ≥2 cytokine release syndrome, or any grade immune effector cell-associated neurotoxicity syndrome. Estimated 18-month event-free and overall survival were 84% and 100%, respectively. CAR T cells expanded in the blood and cerebrospinal fluid despite patients' MRD-negative status. Comparing clinical samples from patients with relapsed/refractory (R/R) B-ALL from our historical trial (ClinicalTrials.gov identifier: NCT02146924) and patients in CR1, we found that the blood and CAR T-cell products from patients with R/R B-ALL were hyperinflammatory and hyperimmunometabolic, respectively. First-line CAR T-cell therapy was safe and well tolerated and potentially extended remission in patients in MRD-negative CR1. These findings support further investigation of the early use of CAR T-cell therapy for B-ALL. This trial was registered at www.clinicaltrials.gov as NCT05707273.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aldoss I, Goldberg L, Zhang J, et al. CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood Adv. 2026. PMID: 42341322. doi:10.1182/bloodadvances.2026020963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。